Lv Jiapei, Liping Chen, Huaying Wang
Department of Respiratory and Critical Care Medicine, The People's Hospital Affiliated to Ningbo University, Ningbo, China.
J Glob Infect Dis. 2024 May 24;16(2):45-53. doi: 10.4103/jgid.jgid_150_23. eCollection 2024 Apr-Jun.
In coronavirus disease 2019 (COVID-19), particularly in older people, dysregulated immune response and aberrant repair can result in varied severity secondary pulmonary fibrosis (PF). By detecting some indicators, the occurrence and prognosis of fibrosis can be measured, providing directions for COVID-19 treatment.
The research study lasted for 3 months and involved 88 COVID-19 patients. According to the chest radiological examination, 47 (53.41%) individuals were found to have no PF, while 41 (46.59%) showed PF. Clinical data such as inflammation markers, imaging findings, blood gas analysis, and hospital stay length were collected.
With area under the curve values of 0.7413, 0.7741, and 0.7048, respectively, and the study of the receiver operating characteristic curve demonstrated that mucin 1 (MUC1), carcinoembryonic antigen (CEA), and CXC chemokine receptor 10 (CXCL10) could diagnose the presence of COVID-19 PF. To evaluate the possibility of PF following severe acute respiratory syndrome coronavirus-2 infection, we established particular values for MUC1, CEA, and CXCL10 (1.296 ng/ml, 4.315 ng/ml, and 32.77 ng/ml, respectively). The survival curve for hospital days indicated that the length of hospital stays positively correlated with these three factors ( < 0.01). Transforming growth factor-beta did not correlate significantly with the severity of COVID-19 or PF.
The results of this study suggested that the MUC1, CEA, and CXCL10 can be employed to explore the severity of secondary PF in COVID-19.
在2019冠状病毒病（COVID-19）中，尤其是在老年人中，免疫反应失调和异常修复可导致继发性肺纤维化（PF）严重程度各异。通过检测一些指标，可以衡量纤维化的发生和预后，为COVID-19治疗提供指导。
该研究持续了3个月，纳入了88例COVID-19患者。根据胸部放射学检查，发现47例（53.41%）患者无PF，而41例（46.59%）显示有PF。收集了炎症标志物、影像学检查结果、血气分析和住院时间等临床数据。
受试者工作特征曲线研究显示，黏蛋白1（MUC1）、癌胚抗原（CEA）和CXC趋化因子受体10（CXCL10）诊断COVID-19相关性PF的曲线下面积值分别为0.7413、0.7741和0.7048。为评估严重急性呼吸综合征冠状病毒2感染后发生PF的可能性，我们确定了MUC1、CEA和CXCL10的特定值（分别为1.296 ng/ml、4.315 ng/ml和32.77 ng/ml）。住院天数的生存曲线表明，住院时间与这三个因素呈正相关（<0.01）。转化生长因子-β与COVID-19或PF的严重程度无显著相关性。
本研究结果表明，MUC1、CEA和CXCL10可用于探究COVID-19继发性PF的严重程度。
